On April 1, 2022, Cheplapharm Arzneimittel GmbH (“Cheplapharm”) signed an agreement with F. Hoffmann-La Roche Ltd. to acquire the worldwide rights to Xeloda® (capecitabine). Under the terms of the agreement, Cheplapharm will receive product rights for Xeloda® in certain countries worldwide including the USA.
Beginning April 4, 2023, please direct any clinical product questions to Cheplapharm’s US partner, H2 Pharma, by phone at 1 (334) 647-1947.
Who should I contact if I have side effect concerns or have an adverse event to report on the product?
Beginning April 4, 2023, you may contact Cheplapharm’s US partner, H2 Pharma, by phone at 1-866-995-4272 or by email: [email protected] if you have side effect concerns or you would like to report an adverse event. You may also report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
